| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/14/2023 | 457.38% | Cantor Fitzgerald | → $17 | Reiterates | Overweight → Overweight |
| 08/14/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 05/16/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 03/31/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/17/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 01/26/2023 | 555.74% | HC Wainwright & Co. | $26 → $20 | Maintains | Buy |
| 11/24/2021 | 752.46% | HC Wainwright & Co. | → $26 | Initiates Coverage On | → Buy |
| 04/05/2021 | 719.67% | Alliance Global Partners | → $25 | Initiates Coverage On | → Buy |
| 03/29/2021 | 555.74% | JonesTrading | → $20 | Initiates Coverage On | → Buy |
| 03/15/2021 | 555.74% | Cantor Fitzgerald | $15 → $20 | Maintains | Overweight |
| 02/10/2021 | 621.31% | Canaccord Genuity | → $22 | Initiates Coverage On | → Buy |
| 11/20/2020 | 391.8% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
What is the target price for Ocuphire Pharma (OCUP)?
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $20.00 expecting OCUP to rise to within 12 months (a possible 555.74% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ocuphire Pharma (OCUP)?
The latest analyst rating for Ocuphire Pharma (NASDAQ: OCUP) was provided by HC Wainwright & Co., and Ocuphire Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Ocuphire Pharma (OCUP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocuphire Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocuphire Pharma was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Ocuphire Pharma (OCUP) correct?
While ratings are subjective and will change, the latest Ocuphire Pharma (OCUP) rating was a reiterated with a price target of $0.00 to $20.00. The current price Ocuphire Pharma (OCUP) is trading at is $3.05, which is within the analyst's predicted range.